Case Sharing Prof. Baoli: Facing Difficulties, Selinexor Lights the Light of Hope for MM Patients After Multi-line Relapse
Time of Update: 2022-03-06
/>3g/L, κ light chain: 5170mg/dl, bone marrow showed clonal plasma cells 29%, bone marrow biopsy showed plasmacytoma. FISH showed that 1q21 amplification-positive cells accounted
2021 ASH deep ploughs MM, broad extension new disease, Isatuximab research progress express
Time of Update: 2022-01-10
, et al. 2021ASH. Oral516. MAT-CN-2132308 statement 1. This material is intended to convey cutting-edge information, and does not constitute a recommendation or publicity for any drugs or diagnosis and treatment
A new end point for MM treatment?
Time of Update: 2022-01-09
The results of the study showed that compared with placebo, ixazomib can significantly improve the PFS of MRD+ patients at the time of enrollment (median PFS 18.
Celiniso combined with Vd regimen can achieve excellent efficacy in all subgroups of R/R MM
Time of Update: 2021-12-05
Figure 1: Patients with different cytogenetic subgroups between the two treatment groups have high risk of PFS (78.
2021 ASH is very promising. Regarding the continuous treatment of multiple myeloma, the results of the US MM-6 study have been updated!
Time of Update: 2021-12-04
Society of Hematology (ASH) Annual Meeting will be held in Atlanta, USA on December 11-14, 2021 in a combination of online and offline . The results of the US MM-6 research update
Gathering in the Cloud, Peak Dialogue-Professor Usmani talks about optimizing treatment for relapsed MM
Time of Update: 2021-11-15
relapse after 27 cycles . Finally, Professor Saad Z. Usmani also introduced the exploration of new small-molecule targeted drugs in RRMM, including XPO-1 inhibitor Selinexor
An article to understand the application progress of ADCs, bispecific antibodies and trispecific antibodies targeting BCMA in MM
Time of Update: 2021-11-04
. Table: Bispecific antibodies in clinical development of multiple myeloma Finally, trispecific antibodies are in the pre-clinical development stage, with dual MM surface marker targeting effects, trying to increase the specificity of MM cells .
MM, and new drug solutions are worthy of further exploration
Time of Update: 2021-10-11
of the elderly MM patients in the study underwent second-generation sequencing. The test results showed that most of the patients were at high risk of cytogenetics. The efficacy of the three-drug combination regimen in this part
2021 IMW BCMA CAR-T therapy cilta-cel treatment of MM research results update
Time of Update: 2021-10-02
Research conclusions At a median follow-up of 18 months, cilta-cel achieved early, lasting and deep disease remission in patients with relapsed and refractory MM, and its safety was controllable .
Research shows that the blood pressure of the elderly is better to be controlled within 130 mm Hg
Time of Update: 2021-09-18
to control the blood pressure of the elderly within 130 mmHg Expert: The latest research
EHA Education｜Professor Mateos: The future of MM immunotherapy
Time of Update: 2021-08-08
The updated data 3 of the 17th International Myeloma Symposium (IMW) in 2019 showed that compared with VTd, the ≥CR rate and MRD negative rate after consolidation treatment in the D-VTd group were significantly higher, and PFS benefited more .
Reduce the risk of disease progression by 37% Janssen CD38 antibody combination approved for second-line treatment of MM
Time of Update: 2021-08-02
S. FDA has approved Darzalex Faspro in combination with pomalidomide and dexamethasone (Pd) for the treatment of multiple myeloma that has previously received at least one pre-treatment ( MM) Adult patients .
JCO: Phase 3 TOURMALINE-MM1 trial of patients with relapsed/refractory MM who were treated
Time of Update: 2021-06-21
A lower risk ratio was observed in a predetermined subgroup, suggesting that the ixazomib-Rd regimen has greater OS benefits compared to placebo-Rd : insensitive to any treatment (HR 0.
Efficacy of ixazomib maintenance therapy in high-risk MM patients after 2021 ASCO AlloHCT
Time of Update: 2021-06-17
A phase II study (NCT02440464) evaluated the efficacy of alloHCT and subsequent maintenance therapy with ixazomib in high-risk MM patients receiving a combination of low-dose fludarabine, malphalan, and bortezomib .
2021 EHA Big Coffee Talks Professor Fu Weijun: First Look at the Progress of MM&AL Immunotherapy
Time of Update: 2021-06-17
≥PR were re-randomized into groups and received DARA maintenance treatment or observation respectively. Compare the two The efficacy of the group . The median follow-up
Deeply understand the continuous treatment of multiple myeloma, the most important points are here | MM continuous treatment series
Time of Update: 2021-06-01
>One-minute quick overview of the main points The goal of myeloma treatment is to control the "Darwinian model" of multiple myeloma. Continuous treatment includes maintenance therapies, as well as different types
the goal of "deep remission and longer survival" for the first relapse of MM
Time of Update: 2021-05-22
Daratumumab injection (generic name in English: daratumumab) on the approval of the new indication of Daratumumab in China. The combination of lenalidomide and dexamethasone (Dara-Rd) or the combination of bortezomib and dexamethasone (Dara
Nat Commun: BCMA/CS1 bispecific CAR can prevent antigen escape during CAR-T treatment of MM
Time of Update: 2021-05-20
gov/32385241/" target="_blank" rel="noopener">Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma .
Sanofi Sarclisa's combination of carfilzomib and dexamethasone is approved in the EU for the treatment of MM
Time of Update: 2021-05-09
15 months, the pre-planned interim analysis received Sarclisa plus carfilzomib and dexamethasone (Sarclisa combined Treatment group; n=179) The median PFS of the treated patients has not yet reached.
